<DOC>
	<DOCNO>NCT01200784</DOCNO>
	<brief_summary>Study hypothesis : Nicotinamide inhibit gastrointestinal phosphate absorption serum phosphate level dialysis patient dose dependent manner .</brief_summary>
	<brief_title>Nicotinamide Hemodialysis Patients With Hyperphosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>hemodialysis since 3 month long hemodialysis frequency 3 time weekly stable phosphate binder dose since one month screen serum phosphate level &lt; 2,42 mmol/l screen serum phosphate level &gt; 1,52 mmol/l wash phase stable treatment vitamin D analogues since one month screen congestive heart failure acute bleeding complication acute myocardial infarction peptic ulcer serious liver damage poorly control diabetes severe visual impairment uncontrolled high blood pressure thrombocyte count &lt; 120/nl difficulty swallow dysphagia diminish intestinal motility , megacolon , pseudo mechanical obstruction gastroparesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>